Nu Skin Enterprises, Inc.

Nu Skin Enterprises, Inc. Earnings Recaps

NUS Consumer Staples 3 recaps
Next earnings: February 11, 2027 (estimated) · full calendar
Q3 2026 Nov 8, 2026

Nu Skin shares fell 8.9% after earnings, despite revenue and adjusted EPS landing within the company’s guidance range. The likely disappointment was continued pressure in the core business: customer and sales metrics remain under pressure, and management’s outlook for Q4 relies on anticipated sequential revenue growth rather than describing a recovery already underway.

Key takeaways
  • Q3 revenue was $311 million and adjusted EPS was $0.10, both within guidance.
  • Management said overall customer and sales metrics remain under pressure, while focusing on rebuilding sales-channel engagement and productivity.
  • Prysm iO has been placed in approximately 41,000 devices, with 4.5 million scans completed. After the app’s 2.0 update, scan-to-purchase conversion more than doubled to 10%.
  • LifePak sales grew nearly 3% year to date; the company also cited strong year-over-year revenue growth at its Rhyz manufacturing platform, without providing a figure.
  • For Q4, management anticipates sequential revenue growth. Nu Skin is preparing for India’s formal launch in the first half of 2027 and says its operating changes are intended to improve efficiency and profitability over time.
Q2 2026 Aug 13, 2026

Nu Skin’s shares dropped 11.3% following the quarter, reflecting investor disappointment primarily driven by cautious full-year guidance and ongoing challenges in sales force recruitment and leadership development, suggesting deceleration in core business momentum.

Key takeaways
  • Q2 revenue reached approximately $320 million, supported by early growth in the Prysm iO device placements, which increased nearly 30% quarter-over-quarter to over 39,000 units.
  • Adjusted EPS landed near the midpoint of the prior range, reflecting focus on profitability despite operational headwinds.
  • Sales force recruitment and leadership development remain below levels necessary for sustained growth, limiting channel expansion despite global compensation framework adjustments.
  • The company updated full-year revenue and EPS guidance downward, signaling caution about the near-term outlook.
  • Continued investment in Prysm iO innovation and emerging markets aims to drive long-term growth but results have yet to translate into immediate top-line acceleration.
Q3 2025 Nov 8, 2025

Nu Skin Enterprises reported Q3 2025 revenue of $364 million, aligning with guidance, and delivered an EPS of $0.34, reflecting robust performance amid macro challenges. The company is poised for growth with the upcoming introduction of its Prysm iO wellness platform and entry into the Indian market.

Key takeaways
  • Revenue declined year-over-year but remained within guidance; North America faced transformation challenges while Latin America grew 53%.
  • Launch of Prysm iO, an intelligent wellness platform, scheduled for limited previews in Q4, aiming to enhance customer engagement and lifetime value.
  • Expansion into India is a strategic focus, targeting a growing middle class with a tailored product portfolio and compensation plan to boost market presence.
  • Sequential growth noted in Europe, Africa, South Korea, and Southeast Asia, signaling recovery in key international markets.
  • Nu Skin's significant investment in intelligent wellness reflective of market trends, with a potential market for nutritional supplements anticipated to surpass $700 billion by 2030.